Search Results - christopher+hulme

3 Results Sort By:
Small Molecule DYRK/CLK Inhibitors and Uses Thereof
This invention is a new composition of matter spanning a 6,6-fused chemotype. The 6,6-analogs display strong inhibitory activity across protein kinases such as the DYRK family, including DYRK1A, DYRK2, and DYRK3, along with inhibiting CLK. The dual DYRK/CLK inhibitors have displayed activity in 3-D organoid models of glioblastoma. It is subsequently...
Published: 6/27/2022   |   Inventor(s): Christopher Hulme, Alessandra Fistrovich, Yeng Jeng Shaw, Sourav Banerjee, Curtis Thorne, Nathan Bedard, Carly Cabel
Category(s): Technology Classifications, Technology Classifications > Healthcare Portfolios
Tunable Fluorescent Indolizine Tetracycles
This technology is tunable fluorescent probes that are able to span the colors of the rainbow. The main benefit of this technology is that it can be prepared in only one or two steps; as opposed to the five to seven steps it would normally take. Not only is this technology quicker, but the cost of goods is also more reasonable and compares very favorably...
Published: 1/18/2022   |   Inventor(s): Christopher Hulme, Nathan Bedard, Andrew Sennett
Category(s): Technology Classifications, Technology Classifications > Life Sciences, Technology Classifications > Research Tools, Technology Classifications > Research Tools > Reagents
Novel Inhibitors of the Androgen Receptor for the Treatment of Castration Resistant Prostate Cancer (CRPC)
This invention is a new class of heterocyclic small-molecules designed to antagonize the androgen receptor. These molecules have promising biological activity in a prostate specific cell line. Background: The primary method for treating early stage prostate cancer is via androgen deprivation therapy because prostate cancer needs androgen in order...
Published: 12/13/2018   |   Inventor(s): Christopher Hulme, Yeng Jeng Shaw, Vijay Gokhale
Category(s): Technology Classifications > Life Sciences > Therapeutics